|
|
|
|
||
Vazkepa recommended for approval in New ZealandVazkepa is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and
RecommendationThat icosapent ethyl should be added to the New Zealand schedule as a prescription medicine. https://www.medsafe.govt.nz/profs/class/Minutes/2021-2025/mccMin26Apr2022.htm |
return to message board, top of board |